This year’s congress of the European Society for Medical Oncology , which took place in Berlin from October 17 to 21, 2025, offered an impressive variety of topics on numerous tumor entities and therapeutic approaches. These were presented in various formats. These included interactive formats such as the “Challenge your Expert” sessions, in which the audience could ask questions, make critical comments and confront the experts with practical challenges. In the “Challenge your Expert-Session-Gynae-Cancers”, David M. Gershenson presented new therapeutic approaches for low-grade serous ovarian cancer (LGSOC). His presentation focused on the development of innovative combination therapies that go beyond the current standards of chemotherapy and hormone therapy and open up new horizons for the treatment of this rare tumor entity.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- BRAF
- Chemotherapy + Letrozole versus Letrozole
- Combination therapy
- Hormonal therapy
- international Phase II/III study GOG 0281
- Johns Hopkins study
- KRAS
- Low grade serous ovarian carcinoma (LGSOC)
- Maintenance therapy
- MAP kinase signaling pathway mutation
- MD Anderson Cancer Center (MDACC)
- Mixed tumors LGSOC and HGSOC
- molecular precision medicine
- NRAS
You May Also Like
- Cardiology
Minimally invasive – the quiet triumph of modern heart surgery
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Age-related neurocognitive disorders
Neuroprotective effects of Ginkgo biloba extract
How origin and place of residence promote CF-associated diabetes
- Patients with leg swelling
DVT and other common DDs with peripheral edema
- Pancreatic Cancer
Innovative early detection with a focus on liquid biopsy and AI
- Cervical Cancer
HPV prevention, screening innovation and sentinel lymph node biopsy
- Polypharmacy: use of eHealth tools in Switzerland